IDH1 and acute myeloid leukemia: As summarized in Table 1, FLT3-ITD and FLT3 tyrosine kinase domain (FLT3-TKD) mutations, as well as RAS, TP53, WT1, and IDH1 mutations were recurrently gained at relapse of AML [65, 69, 76–84].